Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2012, Article ID 269751, 16 pages
http://dx.doi.org/10.1155/2012/269751
Research Article

AS601245, an Anti-Inflammatory JNK Inhibitor, and Clofibrate Have a Synergistic Effect in Inducing Cell Responses and in Affecting the Gene Expression Profile in CaCo-2 Colon Cancer Cells

1MerckSerono Ivrea, Istituto di Ricerche Biomediche “A. Marxer”, RBM S.p.A., 10010 Colleretto Giacosa, Italy
2Department of Medicine and Experimental Oncology, Section of General Pathology, University of Turin, 10125 Turin, Italy
3Department of Anatomy, Pharmacology and Forensic Medicine, Section of Pharmacology and Pharmacognosy, University of Turin,10125 Turin, Italy
4Department of Anatomy, Pharmacology, and Forensic Medicine, Section of Pharmacology and Experimental Therapy, University of Turin, 10125 Turin, Italy

Received 2 August 2011; Revised 29 October 2011; Accepted 1 November 2011

Academic Editor: J. Reddy

Copyright © 2012 Angelo Cerbone et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Lemberger, B. Desvergne, and W. Wahli, “Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology,” Annual Review of Cell and Developmental Biology, vol. 12, pp. 335–363, 1996. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. F. Beck, S. Plummer, P. V. Senior, S. Byrne, S. Green, and W. J. Brammar, “The ontogeny of peroxisome-proliferator-activated receptor gene expression in the mouse and rat,” Proceedings of the Royal Society B, vol. 247, no. 1319, pp. 83–87, 1992. View at Google Scholar · View at Scopus
  3. S. A. Kliewer, S. S. Sundseth, S. A. Jones et al., “Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4318–4323, 1997. View at Publisher · View at Google Scholar · View at Scopus
  4. B. M. Forman, J. Chen, and R. M. Evans, “Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4312–4317, 1997. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Cuzzocrea, R. Di Paola, E. Mazzon et al., “Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha (PPAR-α) in the development of inflammatory bowel disease in mice,” Laboratory Investigation, vol. 84, no. 12, pp. 1643–1654, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. D. Panigrahy, A. Kaipainen, S. Huang et al., “PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 3, pp. 985–990, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. Z. Strakova, P. Mavrogianis, X. Meng et al., “In vivo infusion of interleukin-1β and chorionic gonadotropin induces endometrial changes that mimic early pregnancy events in the baboon,” Endocrinology, vol. 146, no. 9, pp. 4097–4104, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. B. J. Ledwith, T. E. Johnson, L. K. Wagner et al., “Growth regulation by peroxisome proliferators: opposing activities in early and late G1,” Cancer Research, vol. 56, no. 14, pp. 3257–3264, 1996. View at Google Scholar · View at Scopus
  9. M. S. Rao and J. K. Reddy, “Hepatocarcinogenesis of peroxisome proliferators,” Annals of the New York Academy of Sciences, vol. 804, pp. 573–587, 1996. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Dzhekova-Stojkova, J. Bogdanska, and Z. Stojkova, “Peroxisome proliferators: their biological and toxicological effects,” Clinical Chemistry and Laboratory Medicine, vol. 39, no. 6, pp. 468–474, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. S. Laurora, S. Pizzimenti, F. Briatore et al., “Peroxisome proliferator-activated receptor ligands affect growth-related gene expression in human leukemic cells,” Journal of Pharmacology and Experimental Therapeutics, vol. 305, no. 3, pp. 932–942, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. A. Cerbone, C. Toaldo, S. Laurora et al., “4-Hydroxynonenal and PPARγ ligands affect proliferation, differentiation, and apoptosis in colon cancer cells,” Free Radical Biology and Medicine, vol. 42, no. 11, pp. 1661–1670, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. F. Penna, G. Bonelli, F. M. Baccino, and P. Costelli, “Cytotoxic properties of clofibrate and other peroxisome proliferators: relevance to cancer progression,” Current Medicinal Chemistry, vol. 17, no. 4, pp. 309–320, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. P. M. Barger, A. C. Browning, A. N. Garner, and D. P. Kelly, “p38 mitogen-activated protein kinase activates peroxisome proliferator-activated receptor α: a potential role in the cardiac metabolic stress response,” Journal of Biological Chemistry, vol. 276, no. 48, pp. 44495–44501, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. K. A. Burns and J. P. Vanden Heuvel, “Modulation of PPAR activity via phosphorylation,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 952–960, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. G. Martin, H. Duezm, C. Blanquart et al., “Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I,” Journal of Clinical Investigation, vol. 107, no. 11, pp. 1423–1432, 2001. View at Google Scholar
  17. C. Ferrandi, R. Ballerio, P. Gaillard et al., “Inhibition of c-Jun N-terminal kinase decreases cardiomyocyte apoptosis and infarct size after myocardial ischemia and reperfusion in anaesthetized rats,” The British Journal of Pharmacology, vol. 142, no. 6, pp. 953–960, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. M. J. Ramond, M. Martinot-Peignoux, and S. Erlinger, “Dome formation in the human colon carcinoma cell line Caco-2 in culture. Influence of ouabain and permeable supports,” Biology of the Cell, vol. 54, no. 1, pp. 89–92, 1985. View at Google Scholar · View at Scopus
  19. M. A. McGuckin, R. D. Eri, I. Das, R. Lourie, and T. H. Florin, “ER stress and the unfolded protein response in intestinal inflammation,” The American Journal of Physiology, Gastrointestinal and Liver Physiology, vol. 298, no. 6, pp. 820–832, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. C. Zang, H. Liu, J. Bertz et al., “Induction of endoplasmic reticulum stress response by TZD18, a novel dual ligand for peroxisome proliferator-activated receptor α/γ, in human breast cancer cells,” Molecular Cancer Therapeutics, vol. 8, no. 8, pp. 2296–2307, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. D. G. Lemay and D. H. Hwang, “Genome-wide identification of peroxisome proliferator response elements using integrated computational genomics,” Journal of Lipid Research, vol. 47, no. 7, pp. 1583–1587, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. P. C. Heinrich, I. Behrmann, G. Muller-Newen, F. Schaper, and L. Graeve, “Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway,” Biochemical Journal, vol. 334, no. 2, pp. 297–314, 1998. View at Google Scholar · View at Scopus
  23. P. C. Heinrich, I. Behrmann, S. Haan, H. M. Hermanns, G. Müller-Newen, and F. Schaper, “Principles of interleukin (IL)-6-type cytokine signalling and its regulation,” Biochemical Journal, vol. 374, no. 1, pp. 1–20, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. S. Grivennikov, E. Karin, J. Terzic et al., “IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer,” Cancer Cell, vol. 15, no. 2, pp. 103–113, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. J. Bollrath, T. J. Phesse, V. A. von Burstin et al., “gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis,” Cancer Cell, vol. 15, no. 2, pp. 91–102, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. A. van Summeren, J. Renes, F. G. Bouwman et al., “Proteomics investigations of drug-induced hepatotoxicity in HepG2 cells,” Toxicological Sciences, vol. 120, no. 1, pp. 109–122, 2011. View at Publisher · View at Google Scholar · View at PubMed
  27. F. Penna, P. Reffo, G. Muzio et al., “Mechanisms of clofibrate-induced apoptosis in Yoshida AH-130 hepatoma cells,” Biochemical Pharmacology, vol. 77, no. 2, pp. 169–176, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. G. Muzio, M. Maggiora, M. Oraldi, A. Trombetta, and R. A. Canuto, “PPARα and PP2A are involved in the proapoptotic effect of conjugated linoleic acid on human hepatoma cell line SK-HEP-1,” International Journal of Cancer, vol. 121, no. 11, pp. 2395–2401, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. E. F. Wagner and A. R. Nebreda, “Signal integration by JNK and p38 MAPK pathways in cancer development,” Nature Reviews Cancer, vol. 9, no. 8, pp. 537–549, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. O. Gandrillon, N. Ferrand, J. J. Michaille, L. Roze, M. H. Zile, and J. Samarut, “c-erbAα/T3R and RARs control commitment of hematopoietic self-renewing progenitor cells to apoptosis or differentiation and are antagonized by the v-erbA oncogene,” Oncogene, vol. 9, no. 3, pp. 749–758, 1994. View at Google Scholar · View at Scopus
  31. V. Stoka, B. Turk, S. L. Schendel et al., “Lysosomal protease pathways to apoptosis: cleavage of Bid, not pro-caspases, is the most likely route,” Journal of Biological Chemistry, vol. 276, no. 5, pp. 3149–3157, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. S. Kremer-Tal, G. Narla, Y. Chen et al., “Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation,” Journal of Hepatology, vol. 46, no. 6, pp. 645–654, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. Y. H. Hsu, W. L. Lin, Y. T. Hou et al., “Podocalyxin EBP50 ezrin molecular complex enhances the metastatic potential of renal cell carcinoma through recruiting Rac1 guanine nucleotide exchange factor ARHGEF7,” The American Journal of Pathology, vol. 176, no. 6, pp. 3050–3061, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. H. Knupfer and R. Preiss, “Significance of interleukin-6 (IL-6) in breast cancer (review),” Breast Cancer Research and Treatment, vol. 102, no. 2, pp. 129–135, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. S. Rose-John, K. Mitsuyama, S. Matsumoto, W. M. Thaiss, and J. Scheller, “Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease,” Current Pharmaceutical Design, vol. 15, no. 18, pp. 2095–2103, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. B. B. Aggarwal, A. B. Kunnumakkara, K. B. Harikumar et al., “Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?” Annals of the New York Academy of Sciences, vol. 1171, pp. 59–76, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. J. H. Kim, S. C. Lee, J. Ro, H. S. Kang, H. S. Kim, and S. Yoon, “Jnk signaling pathway-mediated regulation of Stat3 activation is linked to the development of doxorubicin resistance in cancer cell lines,” Biochemical Pharmacology, vol. 79, no. 3, pp. 373–380, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. Q. Ding, Q. Wang, and B. M. Evers, “Alterations of MAPK activities associated with intestinal cell differentiation,” Biochemical and Biophysical Research Communications, vol. 284, no. 2, pp. 282–288, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. M. A. Lea, C. Ibeh, N. Shah, and M. P. Moyer, “Induction of differentiation of colon cancer cells by combined inhibition of kinases and histone deacetylase,” Anticancer Research, vol. 27, no. 2, pp. 741–748, 2007. View at Google Scholar · View at Scopus
  40. A. Orchel, Z. Dzierzewicz, B. Parfiniewicz, L. Weģlarz, and T. Wilczok, “Butyrate-induced differentiation of colon cancer cells is PKC and JNK dependent,” Digestive Diseases and Sciences, vol. 50, no. 3, pp. 490–498, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Rottmann and B. Lüscher, “The Mad side of the Max network: antagonizing the function of Myc and more,” Current Topics in Microbiology and Immunology, vol. 302, pp. 63–122, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. C. Diradourian, J. Girard, and J. P. Pégorier, “Phosphorylation of PPARs: from molecular characterization to physiological relevance,” Biochimie, vol. 87, no. 1, pp. 33–38, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. C. Rachez, B. D. Lemon, Z. Suldan et al., “Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex,” Nature, vol. 398, no. 6730, pp. 824–828, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. M. R. Dotson, C. X. Yuan, R. G. Roeder et al., “Structural organization of yeast and mammalian mediator complexes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 26, pp. 14307–14310, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. C. K. Glass and M. G. Rosenfeld, “The coregulator exchange in transcriptional functions of nuclear receptors,” Genes and Development, vol. 14, no. 2, pp. 121–141, 2000. View at Google Scholar · View at Scopus
  46. Y. Shang, X. Hu, J. DiRenzo, M. A. Lazar, and M. Brown, “Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription,” Cell, vol. 103, no. 6, pp. 843–852, 2000. View at Google Scholar · View at Scopus
  47. A. Sharma, A. S. Meena, and M. K. Bhat, “Hyperthermia-associated carboplatin resistance: differential role of p53, HSF1 and Hsp70 in hepatoma cells,” Cancer Science, vol. 101, no. 5, pp. 1186–1193, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. R. M. Ray, S. Bhattacharya, and L. R. Johnson, “Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1,” Apoptosis, vol. 16, no. 1, pp. 35–44, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. I. Avis, A. Martínez, J. Tauler et al., “Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition,” Cancer Research, vol. 65, no. 10, pp. 4181–4190, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. J. M. Lehmann, J. M. Lenhard, B. B. Oliver, G. M. Ringold, and S. A. Kliewer, “Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs,” Journal of Biological Chemistry, vol. 272, no. 6, pp. 3406–3410, 1997. View at Publisher · View at Google Scholar · View at Scopus